Enzolytics Inc (ENZC)

[foxi]

Page 18:

https://www.otcmarkets.com/otcapi/company/financial-report/344142/content

Enzolytics has created Class switched IgA1/2 Clone 3 Antibodies. This therapy will expectedly provide a protective immunological defense against an initial exposure to HIV virus at mucosal surfaces, such as occurs in the passage of the virus from mother to child through maternal breastfeeding. HIV mucosal infection plays a critical role in virus transmission and AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting CD4+ T helper cells independently of the virus transmission route. Although current anti-retroviral therapy helps control HIV infection in most patients, it cannot eradicate the virus from the human host. Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) have become the most promising approach to preventing HIV transmission. Thus, the development of Class switched Clone 3 IgA1/IgA2 is highly significant.

Thanks for highlighting that and also pointing out they may be sitting on an end-to-end cure.



Edit: Also for Covid:

#ENZC has created "class-switched" IgA Antibodies for #HIV.
Additionally respiratory virus, #SARSCoV2 may require higher levels of mucosal immunity to block transmission hence we are producing IgA Antibodies for SARS-CoV-2. #mucosalimmunity #sciencewillwin pic.twitter.com/CbkrbiMOJA

— Gaurav Chandra M.D. (@drgauravchandra) August 22, 2022

#ENZC has created "class-switched" IgA Antibodies for #HIV.
Additionally respiratory virus, #SARSCoV2 may require higher levels of mucosal immunity to block transmission hence we are producing IgA Antibodies for SARS-CoV-2. #mucosalimmunity #sciencewillwin